Multiple Myeloma
Conditions
Interventions
The treatment group with Selinexor:None
The treatment group without Selinexor:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age> = 18 years, gender is not limited; 2. Confirmed diagnosis of MM according to IMWG criteria, and at least one of the following high-risk factors: t(4,14), t(14,16), t(14,20), del(17/17p), del(13), 1q amplification, R-ISS stage III, plasma cell leukemia, central involvement, combined with extramedullary clonal plasma cells, etc.; 3. Have not received any anti-MM treatment regimen in the past or have received anti-MM therapy regimen without recurrence or refractory.
Exclusion criteria
Exclusion criteria: 1.The patient has previously received SINE (including selinexor), or has a suspected allergy to SINE or similar drugs. 2.The patient has participated in the use of investigational drugs in other anti - tumor clinical trials within 3 weeks. 3.There are mental illnesses/social situations that limit compliance with the study requirements. 4.The patient is unable to swallow oral medications, or is unable or unwilling to abide by the drug administration requirements. 5.Pregnant women, lactating women, or women of childbearing age who are planning to conceive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival, PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Response Rate, ORR;Duration of Response, DOR; | — |
Countries
China
Contacts
Public ContactZhang Li
West China Hospital of Sichuan University
Outcome results
None listed